1. Home
  2. AHCO vs ZYME Comparison

AHCO vs ZYME Comparison

Compare AHCO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AHCO
  • ZYME
  • Stock Information
  • Founded
  • AHCO 2012
  • ZYME 2003
  • Country
  • AHCO United States
  • ZYME United States
  • Employees
  • AHCO N/A
  • ZYME N/A
  • Industry
  • AHCO Medical/Nursing Services
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • AHCO Health Care
  • ZYME Health Care
  • Exchange
  • AHCO Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • AHCO 1.2B
  • ZYME 1.2B
  • IPO Year
  • AHCO N/A
  • ZYME 2017
  • Fundamental
  • Price
  • AHCO $9.20
  • ZYME $18.62
  • Analyst Decision
  • AHCO Strong Buy
  • ZYME Strong Buy
  • Analyst Count
  • AHCO 5
  • ZYME 8
  • Target Price
  • AHCO $13.40
  • ZYME $23.29
  • AVG Volume (30 Days)
  • AHCO 884.3K
  • ZYME 693.8K
  • Earning Date
  • AHCO 11-04-2025
  • ZYME 10-30-2025
  • Dividend Yield
  • AHCO N/A
  • ZYME N/A
  • EPS Growth
  • AHCO N/A
  • ZYME N/A
  • EPS
  • AHCO 0.54
  • ZYME N/A
  • Revenue
  • AHCO $3,240,757,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • AHCO $0.89
  • ZYME $107.76
  • Revenue Next Year
  • AHCO $6.84
  • ZYME $2.35
  • P/E Ratio
  • AHCO $16.97
  • ZYME N/A
  • Revenue Growth
  • AHCO N/A
  • ZYME 95.94
  • 52 Week Low
  • AHCO $7.11
  • ZYME $9.03
  • 52 Week High
  • AHCO $11.63
  • ZYME $19.50
  • Technical
  • Relative Strength Index (RSI)
  • AHCO 51.97
  • ZYME 76.06
  • Support Level
  • AHCO $8.62
  • ZYME $16.20
  • Resistance Level
  • AHCO $9.12
  • ZYME $19.50
  • Average True Range (ATR)
  • AHCO 0.31
  • ZYME 0.66
  • MACD
  • AHCO 0.02
  • ZYME 0.10
  • Stochastic Oscillator
  • AHCO 48.71
  • ZYME 71.95

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: